Pear Therapeutics, Inc.
PEAR · NASDAQ
12/31/2022 | 9/30/2022 | 6/30/2022 | 3/31/2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -37.2% | 23.8% | 19.9% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 32% | 37.4% | 27.2% | 46.1% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -1,136.8% | -652.2% | -995.5% | -1,263.8% |
| Other Income/Exp. Net | $0 | -$0 | $0 | $0 |
| Pre-Tax Income | -$0 | -$0 | $0 | -$0 |
| Tax Expense | -$0 | $0 | -$0 | -$0 |
| Net Income | $0 | -$0 | $0 | -$0 |
| % Margin | 1,123.9% | -852.7% | 1,326.8% | -472.1% |
| EPS | 0.21 | -0.25 | 0.3 | -0.094 |
| % Growth | 184% | -183.3% | 418.8% | – |
| EPS Diluted | 0.21 | -0.25 | 0.3 | -0.094 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | -$0 | $0 | -$0 | -$0 |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -1,259.3% | -531.7% | -2,124.5% | -1,649.4% |